title: Immunotherapy for glioblastoma: the devil is in the details.
authors.forename: Maciej S
authors.initials: MS
authors.lastname: Lesniak
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000532:radiotherapy; D019496:Cancer Vaccines / Q000276:immunology*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D017322:Clinical Trials, Phase II as Topic; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D066246:ErbB Receptors / Q000235:genetics* / Q000276:immunology*; D005909:Glioblastoma / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000532:radiotherapy; D006801:Humans; D009154:Mutation / Q000187:drug effects / Q000528:radiation effects; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D016019:Survival Analysis; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D019496:Cancer Vaccines; C410723:epidermal growth factor receptor VIII; D003606:Dacarbazine; D066246:ErbB Receptors; D000077204:Temozolomide